- Senior Investigator, Experimental Transplantation and Immunology Branch
Dr. Gress received his M.D. from Baylor College of Medicine and his internal medicine residency and oncology fellowship training at the Johns Hopkins Hospital and the NCI. His research interests have been in the area of transplantation immunology with emphasis on the regulation of allogeneic responses and the mechanisms by which peripheral lymphocyte populations are generated and maintained. Dr. Gress is also chief of the Medical Oncology Clinical Research Unit and head of the Transplantation Immunology Section, Experimental Immunology Branch.
- (2020). The Abundance and Availability of Cytokine Receptor IL-2R beta (CD122) Constrain the Lymphopenia-Induced Homeostatic Proliferation of Naive CD4 T Cells. JOURNAL OF IMMUNOLOGY. 204(12), 3227-3235.
- (2020). Y-90-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 35(4), 249-261.
- (2020). Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (vol 26, pg 270, 2020). NATURE MEDICINE. 26(5), 803-803.
- (2020). Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. NATURE MEDICINE. 26(2), 270-+.